Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALZN 002

Next Previous
Search
Drug Profile

ALZN 002

Alternative Names: AL-002-Alzamend Neuro; ALZN-002; CAO-22W; E22-W; E22-W42

Latest Information Update: 05 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of South Florida
  • Developer Alzamend Neuro; University of South Florida
  • Class Alzheimer vaccines; Cell therapies; Dendritic cell vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alzheimer's disease

Most Recent Events

  • 03 Apr 2023 Phase-I/II clinical trials in Alzheimer's disease in USA (Parenteral) (NCT05834296)
  • 03 Apr 2023 Alzamend Neuro plans a phase I/IIa trial and dose first patient for Alzheimer's disease in first quarter of 2023 (ALZN002-01)
  • 28 Dec 2022 Alzamend Neuro and The University of Miami Miller School of Medicine enters into a agreement for ALZN 002

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top